Table Graph
      published meta-analysis   sensitivity analysis   studies

ivermectin in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsKirti, 2021 0.12 [0.01; 2.36] 0.12[0.01; 2.36]Kirti, 202110%112NAnot evaluable clinical improvement (7-day)detailed resultsKirti, 2021 0.90 [0.77; 1.06] 0.90[0.77; 1.06]Kirti, 202110%112NAnot evaluable hospital dischargedetailed resultsKirti, 2021 1.20 [0.73; 1.98] 1.20[0.73; 1.98]Kirti, 202110%112NAnot evaluable mechanical ventilationdetailed resultsKirti, 2021 0.20 [0.00; 8.69] 0.20[0.00; 8.69]Kirti, 202110%112NAnot evaluable viral clearance detailed resultsChaccour, 2020 0.92 [0.77; 1.09] 0.92[0.77; 1.09]Chaccour, 202010%24NAnot evaluable viral clearance by day 7detailed resultsChaccour, 2020 0.92 [0.77; 1.09] Kirti, 2021 0.80 [0.43; 1.50] 0.91[0.77; 1.08]Chaccour, 2020, Kirti, 202120%136lownot evaluable ICU admissiondetailed resultsKirti, 2021 0.90 [0.30; 2.70] 0.90[0.30; 2.70]Kirti, 202110%112NAnot evaluable adverse eventsdetailed resultsChaccour, 2020 1.00 [0.20; 5.07] 1.00[0.20; 5.07]Chaccour, 202010%24NAnot evaluable0.02.01.0relative treatment effectwww.metaEvidence.org2024-05-06 12:10 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 684,886 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons